We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

1 hedge funds and large institutions have $759K invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 174 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 177 → 1 (-176)

100% less capital invested

Capital invested by funds: $944M → $759K (-$943M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 174

Holders
1
Holders Change
-176
Holders Change %
-99.44%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
174
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$94.3M
2
AC
Armistice Capital
New York
-$92.8M
3
RG
Redmile Group
California
-$83.3M
4
DM
Deerfield Management
New York
-$80.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$71.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$759K – – –
BlackRock
2
BlackRock
New York
– -$94.3M -5,994,276 Closed
AC
3
Armistice Capital
New York
– -$92.8M -5,900,000 Closed
RG
4
Redmile Group
California
– -$83.3M -5,296,643 Closed
DM
5
Deerfield Management
New York
– -$80.7M -5,127,270 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$71.8M -4,565,044 Closed
State Street
7
State Street
Massachusetts
– -$48.7M -3,098,806 Closed
Goldman Sachs
8
Goldman Sachs
New York
– -$30.9M -1,962,841 Closed
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
– -$25.3M -1,606,132 Closed
Morgan Stanley
10
Morgan Stanley
New York
– -$24.2M -1,539,826 Closed
PCH
11
Polar Capital Holdings
United Kingdom
– -$23.6M -1,500,000 Closed
FLSM
12
Frazier Life Sciences Management
California
– -$22.9M -1,455,837 Closed
N
13
Nuveen
North Carolina
– -$22.4M -1,425,282 Closed
Geode Capital Management
14
Geode Capital Management
Massachusetts
– -$19.7M -1,254,317 Closed
EA
15
Emerald Advisers
Pennsylvania
– -$16.4M -1,044,871 Closed
EMFAT
16
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$13M -824,402 Closed
JFG
17
Jefferies Financial Group
New York
– -$12.9M -822,515 Closed
Assenagon Asset Management
18
Assenagon Asset Management
Luxembourg
– -$12.7M -809,923 Closed
Millennium Management
19
Millennium Management
New York
– -$12.5M -797,100 Closed
PHP
20
Parkman Healthcare Partners
Connecticut
– -$11.5M -729,230 Closed
B
21
Braidwell
Connecticut
– -$9.59M -609,643 Closed
TCM
22
Tang Capital Management
California
– -$9.44M -600,000 Closed
NLVP
23
New Leaf Venture Partners
New York
– -$9.08M -576,975 Closed
Charles Schwab
24
Charles Schwab
California
– -$8.36M -531,475 Closed
Renaissance Technologies
25
Renaissance Technologies
New York
– -$8.34M -530,200 Closed
1
2 3 4 5

DCPH Hedge Fund Activity: Q2 2024 in Review

1 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2024, worth a combined $759K — down 100% from $944M a quarter earlier.

Sellers outnumbered buyers: 174 funds closed out of DCPH and 0 opened new positions — a net loss of 174 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $94.3M sold.

  • 1 institutional investor held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2024, down from 177 in Q1 2024.
  • Funds reported $759K of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 174 closed out, a net change of -174 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was BlackRock, an estimated $94.3M sold.

Based on aggregated 13F filings for Q2 2024.